Oxidative stress in Parkinson's disease

Annals of Neurology

Volumn 53, Issue SUPPL. 3, 2003, Pages

  Jenner, Peter ^a   Hunot, ^b   Olanow, ^b   Beal, ^b   Kordower, ^b   Tatton, ^b   Schapira, ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; HYDROXYL RADICAL; NITRIC OXIDE; PEROXYNITRITE; PROTEASOME; SUPEROXIDE; UBIQUITIN;

CELL FUNCTION; CELL VIABILITY; CYTOTOXICITY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; HUMAN; INFLAMMATION; MITOCHONDRION; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW;

ALDEHYDES; APOPTOSIS; CORPUS STRIATUM; DOPAMINE; FREE RADICALS; GLUTATHIONE DISULFIDE; HUMANS; IRON; LIPID PEROXIDATION; MITOCHONDRIA; NERVE DEGENERATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE;

EID: 0037378026     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10483     Document Type: Review

References (169)

1. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996;137:120-123.
2. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997;12:25-31.
3. Kingsbury AE, Mardsen CD, Foster OJ. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov Disord 1998;13:877-884.
4. Kosel S, Egensperger R, von Eitzen U, et al. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol (Berl) 1997;93:105-108.
5. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998;13:221-227.
6. Tatton NA, Maclean-Fraser A, Tatton WG, et al. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 1998;44(suppl 1):S142-8148.
7. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000;166:29-43.
8. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl) 1988;76:550-557.
9. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998;44(suppl 1):S115-S120
10. McNaught KS, Jenner P. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release. Neurosci Lett 2000;285:61-65.
11. McNaught KS, Jenner P. Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem Pharmacol 2000;60:979-988.
12. Iravani MM, Kashefi K, Mander P, et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002;110:49-58.
13. Olanow CW, Jenner P, Tatton NA, Tatton WG, Neurodegeneration and Parkinson's disease. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Williams & Wilkins, 1998:67-103.
14. Fahn S. Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997;8:376-393.
15. Shulman LM, Levodopa toxicity in Parkinson disease: reality or myth? Reality - practice patterns should change. Arch Neurol 2000;57:406-407.
16. Weiner WJ. Is levodopa toxic? Arch Neurol 2000;57:408-410.
17. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827.
18. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989;163:1450-1455.
19. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44(suppl 1):S175-S188.
20. Green JG, Greenmayre JT. Bioenergetics and excitoxicity: The weak excitotoxic hypothesis. In: Olanow CW, Jenner P, Youdim M, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:125-142.
21. Beal F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 1998;44:110-114.
22. Bolanos JP, Almeida A, Stewart V, et al. Nitric oxidemediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997;68:2227-2240.
23. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001; 297:191-194.
24. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
25. Youdim MB, Ben Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 1989;126:47-54.
26. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 1991;136:6-15.
27. Jenner P, Schapira AH, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
28. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 1993;146:6-13.
29. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-1623.
30. Coyle JT, Puttfarcken P, Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-695.
31. Jenner P, Dexter DT, Sian J, et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 1992;32(suppl):S82-S87.
32. Yoshikawa T. Free radicals and their scavengers in Parkinson's disease. Eur Ent Neurol 1993;33(suppl 1):60-68.
33. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-798.
34. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144.
35. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44:S72-S84.
36. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
37. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem 1976;19:37-40.
38. Adams RN, Murrill E, McCreery R, et al. 6-Hydroxydopamine, a new oxidation mechanism. Eur J Pharmacol 1972;17:287-292.
39. Spina MB, Cohen G. Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-507.
40. Cohen G, Heikkila RE. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 1974;249:2447-2452.
41. Olanow CW, Youdim MHB. Iron and neurodegeneration: prospects for neuroprotection. In: Olanow CW, Jenner P, Youdim MHB, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:55-67.
42. Earle KM. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 1968;27:1-14.
43. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
44. Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J Neural Transm 1988;74:199-205.
45. Hirsch EC, Brandel JP, Galle P, et al. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991;56:446-451.
46. Olanow CW. Magnetic resonance imaging in parkinsonism. Neurol Clin 1992;10:405-420.
47. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-346.
48. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982; 33:305-310.
49. Sofic E, Lange KW, Jellinger K, Riederer P, Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
50. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
51. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975;32:114-118.
52. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985;58:343-346.
53. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 1988;86:321-331.
54. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.
55. Johannsen P, Velander G, Mai J, et al. Glutathione peroxidase in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:679-682.
56. Damier P, Hirsch EC, Zhang P, et al. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993;52:1-6.
57. Sian J, Dexter DT, Lees AJ, et al. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994;36:356-361.
58. Yoshida E, Mokuno K, Aoki S, et al. Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 1994;124:25-31.
59. Radunovic A, Porto WG, Zeman S, Leigh PN. Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex. Neurosci Lett 1997;239:105-108.
60. Yoritaka A, Hattori N, Mori H, et al. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. J Neurol Sci 1997;148:181-186.
61. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
62. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990;55:16-20.
63. Jellinger K, Paulus W, Grundke-Iqbal I, et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 1990;2:327-340.
64. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-881.
65. Kuiper MA, Mulder C, van Kamp GJ, et al. Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J Neural Transm 1994;7:109-114.
66. Cabrera-Valdivia F, Jimenez-Jimenez FJ, Molina JA, et al. Peripheral iron metabolism in patients with Parkinson's disease. J Neurol Sci 1994;125:82-86.
67. Connor JR, Snyder BS, Arosio P, et al. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem 1995;65:717-724.
68. Logroscino G, Marder K, Graziano J, et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997;49:714-717.
69. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.
70. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203.
71. Cheng N, Maeda T, Kume T, et al. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res 1996;743:278-283.
72. Mena MA, Casarejos MJ, Carazo A, et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 1996;7:441-445.
73. Masserano JM, Gong L, Kulaga H, et al. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 1996;50:1309-1315.
74. Hoyt KR, Reynolds IJ, Hastings TG. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamateinduced cell death. Exp Neurol 1997;143:269-281.
75. Ziv I, Zilkha-Falb R, Offen D, et al. Levodopa induces apoptosis in cultured neuronal cells - a possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 1997;12:17-23.
76. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478.
77. Han SK, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.
78. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408.
79. Clement MV, Long LH, Ramalingam J, Halliwell B. The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 2002;81:414-421.
80. Ogawa N, Edamatsu R, Mizukawa K, et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 1993;60:242-250.
81. Ogawa N, Asanuma M, Kondo Y, et al. Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 1994;171:55-58.
82. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur Neurol 1994;34(suppl 3):20-28.
83. Hefti F, Melamed E, Bhawan J, Wurtman R. Long term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
84. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984;43:990-993.
85. Lyras L, Zeng BY, McKenzie G, et al. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 2002;109:53-67.
86. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
87. Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638.
88. Whone AL, Remy P, Davis MR, et al. The REAL PET Study: slower progression in early Parkinson's disease treated with ropinirole compound with L-dopa (Abstract S11.006). Presented at: 54th Annual Meeting of the American Academy of Neurology; 2002; Denver, CO.
89. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45:577-582.
90. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
91. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
92. Yoritaka A, Hattori N, Mori H, et al. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. J Neurol Sci 1997;148:181-186.
93. Pearce RK, Owen A, Daniel S, et al. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 1997;104:661-677.
94. Morris CM, Edwardson JA. Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 1994; 3:277-282.
95. McNaught KS, Jenner P. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 1999;73:2469-2476.
96. Castano A, Herrera AJ, Cano J, Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 1998;70:1584-1592.
97. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
98. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
99. Connor JR, Menzies SL, St. Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992;31:75-83.
100. Valberg LS, Flanagan PR, Kertesz A, Ebers GC. Abnormalities in iron metabolism in multiple sclerosis. Can J Neurol Sci 1989;16:184-186.
101. Lestienne P, Nelson J, Riederer P, et al. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem 1990;55:1810-1812.
102. Schapira AH. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov Disord 1994;9:125-138.
103. Mizuno Y, Ikebe S, Hattori N, et al. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1995;1271:265-274.
104. Ikeda H, Markey CJ, Markey SP. Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease. Brain Res 1992;575:285-298.
105. Sian J, Dexter DT, Lees AJ, et al. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994;36:356-361.
106. Mithofer K, Sandy MS, Smith MT, Di Monte D. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Arch Biochem Biophys 1992;295:132-136.
107. Shen XM, Dryhurst G. Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem Res Toxicol 1996;9:751-763.
108. Spencer JP, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 1995;6:1480-1484.
109. Spencer JP, Jenner P, Daniel SE, et al. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem 1998;71:2112-2122.
110. Shen XM, Li H, Dryhurst G. Oxidative metabolites of 5-Scysteinyldopamine inhibit the alpha-ketoglutarate dehydrogenase complex: possible relevance to the pathogenesis of Parkinson's disease. J Neural Transm 2000;107:959-978.
111. Li H, Shen XM, Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4benzothiazine-3-carboxyli c acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. J Neurochem 1998;71:2049-2062.
112. Spencer JP, Whiteman M, Jenner P, Halliwell B. 5-Scysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J Neurochem 2002;81:122-129.
113. Ibi M, Sawada H, Kume T, et al. Depletion of intracellular glutathione increases susceptibility to nitric oxide in mesencephalic dopaminergic neurons. J Neurochem 1999;73:1696-1703.
114. Chen Y, Vartiainen NE, Ying W, et al. Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J Neurochem 2001;77:1601-1610.
115. Hasegawa E, Takeshige K, Oishi T, et al. 1-Methyl-4phenylpyridinium. (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990;170:1049-1055.
116. Cassarino DS, Fall CP, Swerdlow RH, et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1997;1362:77-86.
117. Veech GA, Dennis J, Keeney PM, et al. Disrupted mitochondrial electron transport function increases expression of antiapoptotic bcl-2 and bcl-X(L) proteins in SH-SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress. J Neurosci Res 2000;61:693-700.
118. Hartley A, Cooper JM, Schapira AH. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res 1993;627:349-353.
119. Glinka YY, Youdim MB. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 1995;292:329-332.
120. Ben Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995; 64:718-723.
121. Dagani F, Ferrari R, Anderson JJ, Chase TN. L-dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria. Mov Disord 1991;6:315-319.
122. Cooper JM, Daniel SE, Marsden CD, Schapira AH. L-Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Mov Disord 1995;10:295-297.
123. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
124. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92-97.
125. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998;70:268-275.
126. Alam ZI, Daniel SE, Lees AJ, et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329.
127. Sanchez-Ramos J, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nidro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
128. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-1203.
129. Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999;154:1423-1429.
130. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996;93:2696-2701.
131. Picklo MJ, Amarnath V, McIntyre JO, et al. 4-Hydroxy-2(E)nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 1999;72:1617-1624.
132. Liu W, Kato M, Akhand AA, et al. 4-Hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J Cell Sci 2000;113:635-641.
133. Camandola S, Poli G, Mattson MP. The lipid peroxidation product 4-hydroxy-2,3-nonenal increases AP-1-binding activity through caspase activation in neurons. J Neurochem 2000; 74:159-168.
134. Smith TS, Bennett JP Jr. Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions. Brain Res 1997;765:183-188.
135. Smith TS, Trimmer PA, Khan SM, et al. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptorbinding sites in C57BL/6 mice during MPTP treatment. Brain Res 1997;765:189-197.
136. Lotharius J, O'Malley KL. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 2000; 275:38581-38588.
137. Nakamura K, Bindokas VP, Marks JD, et al. The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol Pharmacol 2000;58:271-278.
138. Przedborski S, Kostic V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridineinduced neurotoxicity. J Neurosci 1992;12:1658-1667.
139. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
140. Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72:355-363.
141. Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW. Mass spectrometric quantification of 3-nitrotyrosine, orthotyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 1999;274:34621-34628.
142. Ferrante RJ, Hantraye P, Brouillet E, Beal MF. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res 1999;823:177-182.
143. Good PF, Hsu A, Werner P, et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998;57:338-342.
144. Giassort BL, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
145. Duda JE, Giasson BI, Chen Q, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000;157:1439-1445.
146. Schulz JB, Matthews RT, Muqit MM, et al. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995;64:936-939.
147. Hantraye P, Brouillet E, Ferrante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996;2:1017-1021.
148. Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse 1997;26:301-316.
149. Przedborski S, Jackson-Lewis V, Yokoyama R, et al, Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996;93:4565-4571.
150. Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403-1409.
151. Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 1990;283:537-541.
152. Bolanos JP, Heales SJ, Peuchen S, et al. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic Biol Med 1996;21:995-1001.
153. Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 1998;95:7631-7636.
154. Barker JE, Heales SJ, Cassidy A, et al. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. Brain Res 1996; 716:118-122.
155. Byun J, Henderson JP, Mueller DM, Heinecke JW. 8-Nitro2′-deoxyguanosine, a specific marker of oxidation by reactive nitrogen species, is generated by the myeloperoxidasehydrogen peroxide-nitrite system of activated human phagocytes. Biochemistry 1999;38:2590-2600.
156. Szabo C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996;93:1753-1758.
157. Ying W, Sevigny MB, Chen Y, Swanson RA. Poly(ADPribose) glycohydrolase mediates oxidative and excitotoxic neuronal death. Proc Natl Acad Sci USA 2001;98:12227-12232.
158. Cosi C, Colpaert F, Koek W, et al. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. Brain Res 1996;729:264-269.
159. Mandir AS, Przedborski S, Jackson-Lewis V, et al. Poly(ADPribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 1999;96:5774-5779.
160. Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998-1009.
161. Hyun DH, Lee M, Hattori N, et al. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 2002;277:28572-28577.
162. Lee MH, Hyun DH, Jenner P, Halliwell B. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J Neurochem 2001;78:32-41.
163. Souza JM, Choi I, Chen Q, et al. Proteolytic degradation of tyrosine nitrated proteins. Arch Biochem Biophys 2000;380:360-366.
164. Jahngen-Hodge J, Obin MS, Gong X, et al. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem 1997;272:28218-28226.
165. Lee H-J, Shin SY, Choi C, et al. Formation and removal of a-synuclein aggregates in cells exposed to mitochondria inhibitors. J Biol Chem 2002;15:5411-5417.
166. Reinheckel T, Sitte N, Ullrich O, et al. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 1998;335:637-642.
167. Okada K, Wangpoengtrakul C, Osawa T, et al. 4-Hydroxy-2nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 1999;274:23787-23793.
168. Hyun D, Lee M, Halliwell B, Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration. J Neurochem 2002;83:360-370.
169. Hyun D, Lee M, Halliwell B, Jenner P. Early stage apoptotic cascade of neuronal cells overexpressing wild type or mutant α-synuclein: the mechanism of neurodegeneration in Parkinson's disease. J Neurochem (in press).